top of page
Search

Happy New year - and UPDATED COVID-19 treatment guidelines!

With the New Year, new guidelines! Our COVID-19 therapeutic working group has revised our COVID-19 management guidelines. Of note, empiric antibiotics are strongly DISCOURAGED for mild and moderate disease. Investigational or off-label therapies should NOT be given outside of clinical trials (several ongoing clinical trials at the MUHC); Criteria are proposed for potential identification of hyperimmune response, with recommendations to consult ID for severe cases.



 
 
 

Recent Posts

See All
Linezolid TDM

INESSS approved the TDM of Linezolid in May 2024 It is now available in the MUHC (via HSJ labs) The ASP committee is happy to publish a...

 
 
 
MUHC ASP annual report 2022-2023

The ASP chairs are happy to publish the MUHC ASP annual report 2022-2023, now available in the Resources section of the MUHC ASP website....

 
 
 
S.aureus bacteremia

The ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus...

 
 
 

Comments

bottom of page